Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine

TC Erciyes University60 enrolled

Overview

The purpose of this study is to determine whether N-acetylcysteine is effective in the prevention of hearing loss in both ears due to aminoglycoside and/or vancomycine induced ototoxicity in peritoneal dialysis patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Drug-induced Ototoxicity in Peritoneal Dialysis Patients

Interventions

N-acetylcysteineDRUG

N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * End-stage renal disease * Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy * Clinical diagnosis of a peritonitis episode in a continuous ambulatory peritoneal dialysis patient * Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode Exclusion Criteria: * Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months * Detection of mechanical occlusion of external ear * Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry * History of a continuous ambulatory peritoneal dialysis related peritonitis

Locations (1)

Erciyes University School of Medicine Department of Nephrology

Kayseri, Turkey (Türkiye)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.